Your browser doesn't support javascript.
loading
Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens.
Nonaka, Tamami; Taguchi, Hiroaki; Uda, Taizo; Hifumi, Emi.
Afiliação
  • Nonaka T; Institute for Research Management, Oita University, 700 Dannoharu, Oita 870-1192, Japan.
  • Taguchi H; Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagaki-cho, Suzuka 510-0293, Japan.
  • Uda T; Nanotechnology Laboratory, Institute of Systems, Information Technologies and Nanotechnologies (ISIT), 4-1 Kyudai-shinmachi, Fukuoka 879-5593, Japan.
  • Hifumi E; Institute for Research Management, Oita University, 700 Dannoharu, Oita 870-1192, Japan.
Int J Mol Sci ; 23(22)2022 Nov 18.
Article em En | MEDLINE | ID: mdl-36430828
ABSTRACT
A catalytic antibody has multiple functions compared with a monoclonal antibody because it possesses unique features to digest antigens enzymatically. Therefore, many catalytic antibodies, including their subunits, have been produced since 1989. The catalytic activities often depend on the preparation methods and conditions. In order to elicit the high catalytic activity of the antibodies, the most preferable methods and conditions, which can be generally applicable, must be explored. Based on this view, systematic experiments using two catalytic antibody light chains, #7TR and H34, were performed by varying the purification methods, pH, and chemical reagents. The experimental results obtained by peptidase activity tests and kinetic analysis, revealed that the light chain's high catalytic activity was observed when it was prepared under a basic condition. These data imply that a small structural modulation of the catalytic antibody occurs during the purification process to increase the catalytic activity while the antigen recognition ability is kept constant. The presence of NaCl enhanced the catalytic activity. When the catalytic light chain was prepared with these preferable conditions, #7TR and H34 hugely enhanced the degradation ability of Amyloid-beta and PD-1 peptide, respectively.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Catalíticos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Catalíticos Idioma: En Ano de publicação: 2022 Tipo de documento: Article